Eurobio Scientific

FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP - Seite 2

• Continued international expansion
  
  

International sales represents 38% of 2023 revenues (against 25% of core business revenues in 2022). This increase is mainly due to the new acquisitions made over the past year in Belgium (BMD), the Netherlands (GenDx) and Italy (DID) as well as increasing cross-selling of the Group's own products.

Integration and international strategy continues in 2024 with the acquisition of the UK company Alpga Biotech that has been the distributor of GenDx for more than 20 years.

Outlook

With the confirmation of the strategic priorities chosen over the last few years, the Eurobio Scientific Group will continue to expand on its three pillars: development of proprietary products, internationalisation and new markets expansion.

Next financial meeting
2023 annual results : April 10, 2024, after market closes

About Eurobio Scientific Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy. Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

Contacts

Eurobio Scientific Group Denis Fortier, Chairman and CEO Olivier Bosc, Deputy CEO/ CFO Tel. [phone]

Calyptus Mathieu Calleux Investors Relations Tel. [phone] - [e-mail]

Attachment

• 20240130_PR_EurobioScientific_CA_TY_23_EN